We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GEHC Stock Gains Following Launch of Revolution Vibe CT Imaging System
Read MoreHide Full Article
Key Takeaways
GEHC's Revolution Vibe CT wins FDA clearance with Unlimited One-Beat Cardiac imaging.
Clinical use cut exam time by 50% and doubled cardiac CT angiography capacity with GEHC's Revolution Vibe
The GEHC system combines AI tools and workflow automation to boost efficiency and comfort.
GE HealthCare (GEHC - Free Report) recently announced that its innovative imaging solution, Revolution Vibe CT system, has received FDA 510(k) clearance. The device is designed to address the most difficult cardiac exams, including patients with arrhythmias, heavily calcified coronaries and valves, stents, or bypasses.
The Revolution Vibe CT system features Unlimited One-Beat Cardiac imaging and integrated AI-powered tools, offering clinicians a fast, powerful, and non-invasive way to identify potential heart blockages. It also includes ECG-less Cardiac, TrueFidelity DL, SnapShot Freeze 2, and Effortless Cardiac Workflow that help optimize image quality and reduce exam time. The device also enhances patient comfort and streamlines workflow.
The clearance is based on data from clinical evaluations demonstrating that the use of Revolution Vibe with Effortless Workflow led to a 50% reduction in exam time and up to five minutes saved in patient preparation per scan. The device also optimized CCTA exam scheduling and doubled CCTA capacity, driven by automated protocol selection, simplified positioning, and minimized reliance on beta blockers and ECG connections. The system’s Unlimited One-Beat Cardiac imaging delivers full-heart clarity at low dose, even in cases without an ECG trace.
Likely Share Price Performance
Shares of GE HealthCare have risen nearly 5.8% since the announcement of the FDA clearance for the Revolution Vibe CT system on Sept. 2. However, the company’s shares have lost 3.2% so far this year against the industry’s 8.2% growth. The S&P 500 Index has gained 10.8% in that period.
Image Source: Zacks Investment Research
The FDA clearance for Revolution Vibe CT system has the potential to drive prospects on the back of rising cardiovascular disease cases, thereby leading to share price gain. Per the company’s press release, cardiovascular disease remains the leading cause of death globally, with projections of more than 23 million deaths annually by 2030. This has resulted in demand for cardiac CT angiography that can drive demand for tools like the Revolution Vibe CT system.
Moreover, the recent adoption of favorable clinical guidelines for cardiac CT, along with positive reimbursement, will also drive procedure growth, potentially ushering in a new era of cardiac imaging with systems like the Revolution Vibe CT. The fast, high-performance solution and minimally invasive features of the Revolution Vibe CT system are likely to keep it ahead of the competition.
Beyond cardiac imaging, Revolution Vibe supports general imaging needs and is designed to help facilities expand their service lines while managing lifecycle costs.
Recent Launches by GEHC
Last month, GE HealthCare launched the Vivid Pioneer, its most advanced AI-powered cardiovascular ultrasound system, designed to elevate diagnostic confidence and streamline clinical workflows. With its next-generation cSound Pioneer architecture, enhanced 2D, 4D, and color flow imaging and AI-driven automation tools, Vivid Pioneer empowers clinicians to achieve faster, more consistent results.
In July, the company launched a new advanced digital X-ray system, Definium Pace Select ET, to enable access and increase efficiency in high-throughput settings. The device is designed to automate manual, repetitive steps and help reduce physical strain. The system leverages AI to ensure accurate patient positioning and consistent image quality across various clinical conditions while streamlining the technologist workflow to maximize patient experience and throughput.
Some other top-ranked stocks in the broader medical space are West Pharmaceutical Services (WST - Free Report) , Medpace Holdings (MEDP - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Medpace Holdings, carrying a Zacks Rank of 2, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, which outpaced the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GEHC Stock Gains Following Launch of Revolution Vibe CT Imaging System
Key Takeaways
GE HealthCare (GEHC - Free Report) recently announced that its innovative imaging solution, Revolution Vibe CT system, has received FDA 510(k) clearance. The device is designed to address the most difficult cardiac exams, including patients with arrhythmias, heavily calcified coronaries and valves, stents, or bypasses.
The Revolution Vibe CT system features Unlimited One-Beat Cardiac imaging and integrated AI-powered tools, offering clinicians a fast, powerful, and non-invasive way to identify potential heart blockages. It also includes ECG-less Cardiac, TrueFidelity DL, SnapShot Freeze 2, and Effortless Cardiac Workflow that help optimize image quality and reduce exam time. The device also enhances patient comfort and streamlines workflow.
The clearance is based on data from clinical evaluations demonstrating that the use of Revolution Vibe with Effortless Workflow led to a 50% reduction in exam time and up to five minutes saved in patient preparation per scan. The device also optimized CCTA exam scheduling and doubled CCTA capacity, driven by automated protocol selection, simplified positioning, and minimized reliance on beta blockers and ECG connections. The system’s Unlimited One-Beat Cardiac imaging delivers full-heart clarity at low dose, even in cases without an ECG trace.
Likely Share Price Performance
Shares of GE HealthCare have risen nearly 5.8% since the announcement of the FDA clearance for the Revolution Vibe CT system on Sept. 2. However, the company’s shares have lost 3.2% so far this year against the industry’s 8.2% growth. The S&P 500 Index has gained 10.8% in that period.
Image Source: Zacks Investment Research
The FDA clearance for Revolution Vibe CT system has the potential to drive prospects on the back of rising cardiovascular disease cases, thereby leading to share price gain. Per the company’s press release, cardiovascular disease remains the leading cause of death globally, with projections of more than 23 million deaths annually by 2030. This has resulted in demand for cardiac CT angiography that can drive demand for tools like the Revolution Vibe CT system.
Moreover, the recent adoption of favorable clinical guidelines for cardiac CT, along with positive reimbursement, will also drive procedure growth, potentially ushering in a new era of cardiac imaging with systems like the Revolution Vibe CT. The fast, high-performance solution and minimally invasive features of the Revolution Vibe CT system are likely to keep it ahead of the competition.
Beyond cardiac imaging, Revolution Vibe supports general imaging needs and is designed to help facilities expand their service lines while managing lifecycle costs.
Recent Launches by GEHC
Last month, GE HealthCare launched the Vivid Pioneer, its most advanced AI-powered cardiovascular ultrasound system, designed to elevate diagnostic confidence and streamline clinical workflows. With its next-generation cSound Pioneer architecture, enhanced 2D, 4D, and color flow imaging and AI-driven automation tools, Vivid Pioneer empowers clinicians to achieve faster, more consistent results.
In July, the company launched a new advanced digital X-ray system, Definium Pace Select ET, to enable access and increase efficiency in high-throughput settings. The device is designed to automate manual, repetitive steps and help reduce physical strain. The system leverages AI to ensure accurate patient positioning and consistent image quality across various clinical conditions while streamlining the technologist workflow to maximize patient experience and throughput.
GE HealthCare Technologies Inc. Price
GE HealthCare Technologies Inc. price | GE HealthCare Technologies Inc. Quote
GEHC’s Zacks Rank & Other Key Picks
Currently, GEHC carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are West Pharmaceutical Services (WST - Free Report) , Medpace Holdings (MEDP - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Medpace Holdings, carrying a Zacks Rank of 2, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, which outpaced the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.